# Oruka Therapeutics drug development expansion

> Live situation record from CLSTR: https://clstr.news/situations/oruka-therapeutics-drug-development-expansion
> Updated: 2026-08-14T23:07:52.000Z. Sources: 5. Developments: 2.

Oruka Therapeutics has expanded the development rights for its lead IL-23 program, ORKA-001, to include inflammatory bowel disease (IBD) following an amended license agreement with Paragon Therapeutics. The company is currently conducting Phase 2b trials for moderate-to-severe plaque psoriasis, with a Phase 3 program scheduled for the first half of 2027.

Management expects its $1.1 billion cash position to fund operations through the anticipated Biologics License Application filing for ORKA-001. Additionally, the company is advancing ORKA-004, a monoclonal antibody targeting TL1A, which is projected to enter clinical development in late 2026.

## Timeline

### 2026-08-14: Oracle and Sumitomo Mitsui see notable stock transactions

Leeward Financial Partners LLC invested $898,000 in Oracle Corporation, while Sumitomo Mitsui Financial Group CFO Kazuyuki Anchi sold 4,000 shares of company stock.

2 sources. https://clstr.news/cluster/executives-at-oruka-therapeutics-and-ovintiv-sell-stock

### 2026-08-10: Oruka Therapeutics expands drug development into inflammatory bowel disease

Oruka Therapeutics is expanding its ORKA-001 program into inflammatory bowel disease, supported by a $1.1 billion cash position and recent stock price highs.

4 sources. https://clstr.news/cluster/oruka-therapeutics-expands-drug-development-into-inflammatory-bowel-disease

---
Cite as: Oruka Therapeutics drug development expansion. CLSTR, https://clstr.news/situations/oruka-therapeutics-drug-development-expansion